The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges

Table 3

Treatment options for high-risk breast cancer patients.

TNBC	>3 lymph nodes affected
Therapy: CTX	Therapy: CTX, anti-HER2, or ET
(i) Anthracycline plus taxane; (ii) Neoadjuvant treatment (presurgical); (iii) Adjuvant treatment (postsurgical); (iv) Addition of carboplatin may improve pCR and event-free survival	(i) Adjuvant treatment with anthracycline plus taxane; (ii) Anti-HER2 treatment if tumor HER2+, and/or endocrine therapy if tumor ER/PR+; (iii) Regimens may also include platinum salts (cisplatin, carboplatin); (iv) Dose-dense or dose-intensified CTX improves outcome in N+ patients

pCR: pathological complete response; CTX: chemotherapy; anthracyclines: doxorubicin, epirubicin; Taxanes: paclitaxel, docetaxel; N+: node-positive. According to AGO guidelines (http://www.ago-online.de/en/guidelines-mamma/march-2016).